PlainRecalls
FDA Drug Critical Class I Terminated

Adrucil (fluorouracil injection, USP) Pharmacy Bulk Package Not for Direct Infusion, 5 g/100 mL (50 mg/mL), For Intravenous Use Only, Rx Only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-3019-11

Reported: July 15, 2015 Initiated: April 28, 2015 #D-1089-2015

Product Description

Adrucil (fluorouracil injection, USP) Pharmacy Bulk Package Not for Direct Infusion, 5 g/100 mL (50 mg/mL), For Intravenous Use Only, Rx Only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-3019-11

Reason for Recall

Presence of Particulate Matter: Black particulate matter was identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
6195 vials
Distribution
Nationwide
Location
Horsham, PA

Frequently Asked Questions

What product was recalled?
Adrucil (fluorouracil injection, USP) Pharmacy Bulk Package Not for Direct Infusion, 5 g/100 mL (50 mg/mL), For Intravenous Use Only, Rx Only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-3019-11. Recalled by Teva Pharmaceuticals USA. Units affected: 6195 vials.
Why was this product recalled?
Presence of Particulate Matter: Black particulate matter was identified as aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 15, 2015. Severity: Critical. Recall number: D-1089-2015.